#London #Australia #Curaleaf #medical cannabis #Inhalation Device

Curaleaf International Launches Revolutionary Medical Device

Curaleaf International has recently made headlines by securing a significant milestone in the medical cannabis sector. Partnering with Jupiter Research LLC, they have launched the Que Medical Inhalation Device (QMID), which is officially registered by Australia's Therapeutic Goods Administration (TGA). This registration, announced on October 2, 2026, marks QMID as the first ever device designed for inhaling Cannabis Sativa L. extracts approved for use in Australia.

This groundbreaking achievement follows an earlier recognition in Europe, where QMID received its EU Medical Device registration last year, confirming its status as a Class IIb Medical Device. By navigating complex regulatory pathways, Curaleaf is now poised to offer a reliable delivery method for medical cannabis in Australia, a market that has seen over a million patients seeking treatment since its inception in 2016.

In addition to its availability in Australia, QMID has also been added to the Web Assisted Notification of Devices (WAND) database in New Zealand, allowing prescribers in the region to access this innovative inhalation device. The endorsement from TGA and Medsafe not only signifies regulatory approval but also demonstrates Curaleaf's dedication to ensuring that patients receive safe and effective medical devices.

Dr. Mikael Sodergren, Chief Medical Officer at Curaleaf International, expressed the significance of this registration by noting that for the first time, clinicians can prescribe a liquid cannabis inhalation device that adheres to formal approval standards, ensuring standardized dosing. This is a major step forward in making cannabis treatment as mainstream as any other prescribed medicine.

The approval process conducted by TGA, which emphasizes rigorous testing and scrutiny, reflects Curaleaf's commitment to ensuring that clients receive the highest standards of safety and effectiveness. CEO Juan Martinez echoed this sentiment, stating, “We are proud that QMID is the first liquid cannabis inhalation device to meet both EU and Australian standards. Moving forward, we aim to extend this technology to more patients, navigating through the necessary regulatory pathways.”

QMID addresses a critical gap in Australia's medical cannabis landscape, where previously, while the medications themselves could be prescribed via regulatory frameworks, the devices for inhalation often remained unapproved. This caused obstacles for practitioners and patients alike, leading to difficulties in accessing compliant means to administer their prescribed treatments.

The device, designed to facilitate the efficient aerosolization of medical cannabis, boasts a user-friendly, compact structure that allows for discreet use. Its complex engineering supports reliable dosing and contributes to the quality of clinical data available for clinicians and patients. Furthermore, the hardware of QMID can only be used with approved cartridges, ensuring compliance with the highest standards of medical device safety.

By finally bridging the gap between approved medications and their administration devices, Curaleaf is significantly shifting the dynamics of the medical cannabis market in Australia and New Zealand. The TGA registration and the availability in New Zealand marks a positive development in a nascent but rapidly evolving sector, showcasing Curaleaf's leadership in product innovation and commitment to accessible, quality healthcare.

Curaleaf International continues to affirm its position as a pioneering force in the cannabis industry. With expansive operations across Europe and North America, its focus on safety, quality, and research underscores the need for reliable cannabis solutions globally. The significant investment made in engineering and regulatory compliance demonstrates Curaleaf's dedication to elevating standards within the industry, ensuring patients can have confidence in the medical cannabis they receive.

As the medical landscape for cannabis continues to mature, the successful rollout of QMID sets a precedent for future developments and lays the groundwork for increased access to medical-grade cannabinoid therapies across Australasia and beyond.

About Curaleaf International

Curaleaf International is a subsidiary of Curaleaf Holdings, Inc., which is helming the future of cannabis through its focus on research and excellence. With its extensive network and unique distribution strategies across Europe, Canada, and Australasia, it is dedicated to delivering safe and legal cannabis products while prioritizing patient needs and regulatory adherence.